The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 06, 2024
Filed:
Jan. 20, 2023
The Sixth Affiliated Hospital, Sun Yat-sen University, Guangdong, CN;
Jun Huang, Guangdong, CN;
Meijin Huang, Guangdong, CN;
Yanhong Deng, Guangdong, CN;
Fengyun Pei, Guangdong, CN;
Jianping Wang, Guangdong, CN;
The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, CN;
Abstract
Disclosed are a pharmaceutical composition for treating locally advanced mismatch repair-proficient/microsatellite stable (pMMR/MSS) colorectal cancer (CRC) and use thereof. The pharmaceutical composition of the present disclosure includes mFOLFOX6, bevacizumab, and a PD-1 inhibitor. Experimental results show that, when the pharmaceutical composition is used to treat 18 locally advanced (T4N×MO) MSS CRC cases, major pathological remission (tumor regression exceeds 90%) is achieved in 14 cases and pathological complete remission (no residual tumor cells) is achieved in 10 cases; tumor marker levels are all lowered to normal levels; there is no fatal serious adverse event (SAE); and the pharmaceutical composition has prominent safety and efficacy. For locally advanced (T4N×MO) pMMR/MSS CRC patients, the pharmaceutical composition can be administered in combination to make a tumor regress, to improve an R0 resection rate and a pathological complete response (pCR) rate and avoid toxic and side effects of three-drug chemotherapy and concurrent chemoradiotherapy.